tailieunhanh - Anti-tumor efects of rivoceranib against canine melanoma and mammary gland tumour in vitro and in vivo mouse xenograft models

Rivoceranib, a novel tyrosine kinase inhibitor, exhibits anti-tumour effects by selectively blocking vascular endothelial growth factor receptor-2 (VEGFR2) in cancer cells. Recently, the therapeutic effects of rivoceranib on solid tumours have been elucidated in human patients. |

TỪ KHÓA LIÊN QUAN